Cellectis SA (CLLS) - Total Liabilities
Based on the latest financial reports, Cellectis SA (CLLS) has total liabilities worth $226.30 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cellectis SA strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cellectis SA - Total Liabilities Trend (2007–2025)
This chart illustrates how Cellectis SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Cellectis SA assets under control.
Cellectis SA Competitors by Total Liabilities
The table below lists competitors of Cellectis SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kalray SA
PA:ALKAL
|
France | €23.73 Million |
|
Lhyfe SA
PA:LHYFE
|
France | €176.05 Million |
|
Forsys Metals Corp.
TO:FSY
|
Canada | CA$358.54K |
|
Jati Tinggi Group Berhad
KLSE:0292
|
Malaysia | RM71.08 Million |
|
Han Chang Pape
KO:009460
|
Korea | ₩207.27 Billion |
|
NH All One REIT Co Ltd
KO:400760
|
Korea | ₩723.86 Billion |
|
Charnic Capital Tbk PT
JK:NICK
|
Indonesia | Rp30.00 Billion |
|
TCM Group
CO:TCM
|
Denmark | Dkr764.30 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Cellectis SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Cellectis SA (CLLS) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis SA (2007–2025)
The table below shows the annual total liabilities of Cellectis SA from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $248.82 Million | -1.46% |
| 2024-12-31 | $252.51 Million | +1.18% |
| 2023-12-31 | $249.57 Million | +84.49% |
| 2022-12-31 | $135.28 Million | -7.09% |
| 2021-12-31 | $145.60 Million | -9.35% |
| 2020-12-31 | $160.62 Million | +43.42% |
| 2019-12-31 | $112.00 Million | +121.48% |
| 2018-12-31 | $50.57 Million | +7.64% |
| 2017-12-31 | $46.98 Million | -17.05% |
| 2016-12-31 | $56.63 Million | -33.11% |
| 2015-12-31 | $84.67 Million | -10.83% |
| 2014-12-31 | $94.95 Million | +153.46% |
| 2013-12-31 | $37.46 Million | +12.10% |
| 2012-12-31 | $33.42 Million | -64.77% |
| 2011-12-31 | $94.86 Million | +396.58% |
| 2010-12-31 | $19.10 Million | +5.44% |
| 2009-12-31 | $18.12 Million | +23.92% |
| 2008-12-31 | $14.62 Million | +41.54% |
| 2007-12-31 | $10.33 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more